Alopecia Areata Market
The alopecia areata market is poised for steady growth, with a strong compound annual growth rate (CAGR) projected from 2026 to 2036. This expansion across the 7MM will be driven by the launch of innovative therapies, including RINVOQ (upadacitinib), coacillium (LH-8), bempikibart, Rezpegaldesleukin (NKTR-358), among others.
According to DelveInsight’s analysis, the Alopecia Areata Market in the 7MM was valued at approximately USD 379 million in 2023. Over the forecast period from 2026 to 2036, this market is projected to grow significantly, reflecting the rising disease burden, increasing awareness, and a robust pipeline of novel therapeutics entering the clinical and commercial landscape.
Alopecia Areata Overview
Alopecia areata is a prevalent autoimmune skin disorder that leads to hair loss on the scalp, face, and occasionally other parts of the body. It affects individuals of all ages, genders, and ethnic backgrounds, making it a widely inclusive condition in terms of its impact.
Alopecia areata has various forms, with the primary types being patchy alopecia areata, alopecia totalis, and alopecia universalis. Other clinical variants include persistent patchy, diffuse, and ophiasis alopecia areata. It is considered a “polygenic disease” due to its genetic predisposition and multifactorial inheritance pattern.
The condition targets hair follicles through an autoimmune mechanism, causing sudden hair loss that often begins in small patches and can expand into larger bald areas. Hair loss may also affect other areas, such as eyelashes, eyebrows, or the beard in men, typically occurring without accompanying redness, rashes, or scarring on the affected skin.
Alopecia Areata is caused by various risk factors, including nutritional deficiencies, systemic illnesses like autoimmune or thyroid disorders, and stress, which disrupts immune function. Genetic predisposition, environmental triggers such as infections or allergens, and certain medications can also contribute, with family history often increasing susceptibility to the condition.
Alopecia Areata Diagnosis
Alopecia areata’s differential diagnosis includes non-scarring hair loss conditions like tinea capitis, trichotillomania, and telogen effluvium. Comorbidities may include autoimmune diseases, atopic conditions, and psychiatric disorders, with age influencing prevalence. Screening involves tests like hair pull, trichogram, dermatoscopy, and biopsy to assess symptoms and clinical signs.
Alopecia Areata Treatment
Alopecia areata treatments range from mild options like topical corticosteroids to systemic corticosteroids for severe cases. Other therapies include topical immunotherapy, methotrexate, cyclosporine, OX40L, and JAK inhibitors. Adjuncts like minoxidil, vitamin D, and zinc offer variable results, while phototherapy and platelet-rich plasma show limited success with relapses.
Alopecia Areata Epidemiology
As the market is derived using a patient-based model, the Alopecia Areata Epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Alopecia Areata, Diagnosed Prevalent Cases of Alopecia Areata, Gender-specific Diagnosed Prevalent Cases of Alopecia Areata, Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata, and Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2022 to 2036.
Key Findings from Alopecia Areata Epidemiological Forecast and Trends
- In 2023, the US accounted for the highest prevalence of alopecia areata with approximately 764 thousand cases, which are expected to increase by 2036.
- In 2023, the UK reported the highest number of diagnosed prevalent cases of alopecia areata among the EU4 and the UK, with approximately 323 thousand cases. Spain followed with around 170 thousand cases, while Italy recorded the lowest diagnosed prevalence, with nearly 100 thousand cases.
- In 2023, Japan reported approximately 167 thousand diagnosed prevalent cases of alopecia areata in females and 107 thousand cases in males, with numbers projected to rise by 2036.
- In 2023, females accounted for 63% of alopecia areata cases in the EU4 and the UK, while males represented 37%. These gender-specific patterns are expected to grow, with overall prevalence projected to increase by 2034.
- In Germany, approximately 89% of alopecia areata cases in 2023 occurred in individuals before the age of 40, while 11% were observed in those above 40, indicating higher susceptibility among younger individuals.
- In 2023, around 14% of alopecia areata cases in the EU4 and the UK were mild, 45% moderate, and 41% severe. These severity patterns are expected to continue, with overall prevalence anticipated to increase by 2036.
Marketed Alopecia Areata Drugs
- OLUMIANT (Baricitinib): Eli Lilly and Company/Incyte Corporation
OLUMIANT is a selective and reversible JAK inhibitor that targets the cytokine signaling pathway associated with alopecia areata. It works by inhibiting the activation of ATPase on JAK, blocking signal transmission to cells via the Signal Transducer and Activator of Transcription (STAT) pathway. This mechanism disrupts inflammation and immune responses involved in the condition. OLUMIANT, acting as a JAK inhibitor, has received regulatory approval in the US, EU, and Japan for the treatment of severe alopecia areata.
- LITFULO (Ritlecitinib): Pfizer
LITFULO (ritlecitinib), developed by Pfizer, is an innovative FDA-approved oral treatment for severe alopecia areata, an autoimmune disorder causing significant hair loss. It works by targeting JAK3 and TEC inhibitors to disrupt immune pathways responsible for hair follicle destruction. LITFULO has been approved for use in the US, EU, and Japan, addressing the needs of individuals aged 12 and older with severe forms of the condition. It also received breakthrough designation, highlighting its potential to transform Alopecia Areata Treatment.
- LEQSELVI (Deuruxolitinib, CTP 543): Sun Pharmaceuticals
LEQSELVI (Deuruxolitinib), developed by Sun Pharmaceutical Industries, is an FDA-approved oral treatment for severe alopecia areata in adults. It works by inhibiting JAK1 and JAK2, targeting immune pathways that contribute to hair loss in the condition. LEQSELVI is taken once daily and has received breakthrough and fast track designation for alopecia areata, offering renewed hope for patients with this debilitating autoimmune disorder.
Emerging Alopecia Areata Drugs
- RINVOQ (Upadacitinib): AbbVie
RINVOQ (upadacitinib), a JAK1-specific oral inhibitor, shows considerable promise for alopecia areata treatment, despite being primarily approved for rheumatoid arthritis and atopic dermatitis. Clinical studies indicate significant hair regrowth and improved quality of life. Currently in Phase III, RINVOQ is projected for Alopecia Areata approval by 2027, potentially adding a compelling treatment option to the commercial landscape.
- Bempikibart (ADX-914): Q32 Bio
Bempikibart (ADX-914) is a fully human antibody that targets the IL-7 Receptor Alpha subunit (IL-7Ra) and Thymic Stromal Lymphopoietin (TSLP), aiming to regulate immune function in autoimmune diseases. Currently in Phase II trials for alopecia areata, both IL-7 and TSLP pathways are linked to T-cell-mediated processes in autoimmune conditions. Q32 Bio has completed enrollment for the Phase II trial, underscoring the competitive intensity of the Alopecia Areata Pipeline.
- Amlitelimab (SAR-445229): Sanofi
Amlitelimab (SAR-445229) is a monoclonal antibody targeting OX40L, a molecule that activates T cells driving autoimmune responses. By blocking the OX40-OX40L pathway, it reduces inflammation and regulates the immune system without widespread immunosuppression. Currently in Phase II trials for alopecia areata, it shows potential as a targeted, effective alternative to traditional immunosuppressive therapies, further reinforcing the dynamism within the emerging Alopecia Areata Drugs segment.
Recent Developments in Alopecia Areata Clinical Trials
- In February 2025, HCW Biologics Inc., a clinical-stage biopharmaceutical company with a market cap of approximately $12.4 million, announced FDA clearance to begin a Phase 1 trial for its drug candidate HCW9302, targeting moderate-to-severe alopecia areata.
- The company’s stock has experienced significant volatility, declining over 76% in the past year, according to InvestingPro data, reflecting broader uncertainties in the Alopecia Areata Market Size trajectory for early-stage biotechs.
- The clinical trial activity around HCW9302 is indicative of the growing investor and scientific interest in addressing unmet needs within the alopecia areata therapeutic space.
Alopecia Areata Companies
The competitive landscape of the Alopecia Areata Companies includes notable players such as Eli Lilly and Company, Pfizer, Incyte Corporation, Sun Pharmaceuticals, AbbVie, Sanofi, Q32 Bio, HCW Biologics, and several other emerging and established pharmaceutical companies. These organizations are collectively accelerating research and commercialization efforts to address the significant unmet medical need in both moderate and severe alopecia areata patient populations across the 7MM.
Conclusion
The Alopecia Areata Market stands at a pivotal juncture, shaped by deepening scientific understanding of the disease’s autoimmune mechanisms and a rapidly maturing therapeutic pipeline. The approval of JAK inhibitors such as baricitinib, ritlecitinib, and deuruxolitinib has fundamentally changed the treatment paradigm, offering patients options that were previously unavailable. As next-generation therapies progress through clinical development, the Alopecia Areata Treatment landscape is expected to grow increasingly sophisticated, with novel mechanisms such as IL-7Ra blockade and OX40L inhibition promising targeted interventions with potentially superior safety profiles.
Epidemiological data confirms the scale of the unmet need – with hundreds of thousands of diagnosed cases across the US, EU4, UK, and Japan – and underscores the commercial opportunity that lies ahead. The Alopecia Areata Pipeline remains vibrant, with multiple Phase II and Phase III assets expected to reach the market within the forecast period, contributing meaningfully to market expansion through 2036.
For patients, caregivers, and healthcare providers, the decade ahead offers genuine optimism backed by clinical evidence, regulatory momentum, and sustained pharmaceutical investment in this long-underserved condition.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
